Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha – can tumor immune escape after immunotherapy accelerate disease progression?

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Strannegård, Örjan ^a   Thorén, Fredrik B ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

immunoediting; Immunotherapy; treatment outcome; Type I interferon

Indexed keywords

ALPHA INTERFERON; DACARBAZINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 84961614117     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1091147     Document Type: Article

References (20)

1. M.Burnet. Cancer - a biological approach. 3. Viruses associated with neoplastic conditions. Br Med J 1957; 1:841–6; PMID:13413231; http://dx.doi.org/10.1136/bmj.1.5023.841
2. D.Hanahan, R.A.Weinberg. Hallmarks of cancer: the next generation. Cell 2011; 144:646–74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
3. G.P.Dunn, C.M.Koebel, R.D.Schreiber. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836–48; PMID:17063185; http://dx.doi.org/10.1038/nri1961
4. G.P.Dunn, A.T.Bruce, H.Ikeda, L.J.Old, R.D.Schreiber. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991–8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
5. M.S.Diamond, M.Kinder, H.Matsushita, M.Mashayekhi, G.P.Dunn, J.M.Archambault, H.Lee, C.D.Arthur, J.M.White, U.Kalinke et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989–2003; PMID:21930769; http://dx.doi.org/10.1084/jem.20101158
6. G.P.Dunn, A.T.Bruce, K.C.Sheehan, V.Shankaran, R.Uppaluri, J.D.Bui, M.S.Diamond, C.M.Koebel, C.Arthur, J.M.White et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722–9; PMID:15951814; http://dx.doi.org/10.1038/ni1213
7. J.Rhodes, J.Ivanyi, P.Cozens. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur J Immunol 1986; 16:370–5; PMID:2422040; http://dx.doi.org/10.1002/eji.1830160410
8. N.B.Finter. Why are there so many subtypes of α interferons? J Interfer Res 1991:185–94
9. R.Stadler, T.Luger, T.Bieber, U.Kohler, R.Linse, K.Technau, R.Schubert, K.Schroth, F.Vakilzadeh, M.Volkenandt et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon α: A controlled, randomised multicentre trial. Acta Oncol 2006; 45:389–99; PMID:16760174; http://dx.doi.org/10.1080/02841860600630954
10. F.B.Thoren, O.Strannegard. Adjuvant interferon: extended follow-up times needed? Lancet Oncol 2011; 12:419; PMID:21536217; http://dx.doi.org/10.1016/S1470-2045(11)70107-3
11. L.H.Finke, K.Wentworth, B.Blumenstein, N.S.Rudolph, H.Levitsky, A.Hoos. Lessons from randomized phase III studies with active cancer immunotherapies–outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25 Suppl 2:B97–B109; PMID:17916465; http://dx.doi.org/10.1016/j.vaccine.2007.06.067
12. F.S.Hodi, M.Butler, D.A.Oble, M.V.Seiden, F.G.Haluska, A.Kruse, S.Macrae, M.Nelson, C.Canning, I.Lowy et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005–10; PMID:18287062; http://dx.doi.org/10.1073/pnas.0712237105
13. J.D.Wolchok, J.S.Weber, M.Maio, B.Neyns, K.Harmankaya, K.Chin, L.Cykowski, V.de Pril, R.Humphrey, C.Lebbé. Four-year survival metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24(8):2174–80; PMID:25210016; http://dx.doi.org/10.1093/annonc/mdu441
14. J.A.Sosman, J.M.Unger, P.Y.Liu, L.E.Flaherty, M.S.Park, R.A.Kempf, J.A.Thompson, P.I.Terasaki, V.K.Sondak. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20:2067–75; PMID:11956267; http://dx.doi.org/10.1200/JCO.2002.08.072
15. P.W.Kantoff, T.J.Schuetz, B.A.Blumenstein, L.M.Glode, D.L.Bilhartz, M.Wyand, K.Manson, D.L.Panicali, R.Laus, J.Schlom et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099–105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597
16. E.J.Small, P.F.Schellhammer, C.S.Higano, C.H.Redfern, J.J.Nemunaitis, F.H.Valone, S.S.Verjee, L.A.Jones, R.M.Hershberg. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089–94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252
17. F.B.Thoren, H.Anderson, O.Strannegard. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunol Immunother 2013; 62:1547–51; PMID:23979447; http://dx.doi.org/10.1007/s00262-013-1458-y
18. J.Kalbfleisch, R.Prentice. The statistical analysis of failure time data. New York: Wiley, 2002
19. Guidance for industry: Clinical considerations for therapeutic cancer vaccines. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2011
20. J.Paul. Targeted survival improvements in clinical trials: are you an absolutist or relativist? Cancer 2015; 121:335–8; PMID:25278175; http://dx.doi.org/10.1002/cncr.29031